


## Velaresol

Cat. No.:	HY-106509
CAS No.:	77858-21-0
Molecular Formula:	C <sub>12</sub> H <sub>14</sub> O <sub>5</sub>
Molecular Weight:	238.24
Target:	Others
Pathway:	Others
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (524.68 mM; ultrasonic and warming and heat to 60°C)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	4.1974 mL	20.9872 mL	41.9745 mL
		5 mM	0.8395 mL	4.1974 mL	8.3949 mL
	10 mM	0.4197 mL	2.0987 mL	4.1974 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (8.73 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (8.73 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (8.73 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	Velaresol (BW 12C) is a potent left-shifting anti-sickling compound in vitro <sup>[1]</sup> . Sickle cell disease is an inherited disorder of the hemoglobin molecule. When hemoglobin molecules are exposed to a variety of environments, the red blood cell hemoglobin polymerizes, twists, and morphs into a sickle shape.
-------------	---

### REFERENCES

[1]. Fitzharris P, et al. The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve. Br J Clin Pharmacol. 1985 Apr;19(4):471-81.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA